# Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

> **NCT00001521** · PHASE3 · COMPLETED · sponsor: **Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)** · enrollment: 66 (actual)

## Conditions studied

- Congenital Adrenal Hyperplasia (CAH)

## Interventions

- **DRUG:** Fludrocortisone
- **DRUG:** Hydrocortisone
- **DRUG:** Letrozole
- **DRUG:** Flutamide
- **DRUG:** Testolactone

## Key facts

- **NCT ID:** NCT00001521
- **Lead sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-06-08
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001521, "Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00001521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*